News Features From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing Todd Neale November 08, 2015
News Conference News AHA 2015 Is Watchman Cost-effective? That Depends Where You Look Todd Neale November 07, 2015
News Daily News First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions Todd Neale October 26, 2015
News Conference News TCT 2015 Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients October 14, 2015
News Conference News TCT 2015 Use of LAA Occlusion in Low-Risk Patients Debated Todd Neale October 11, 2015
News Industry News CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) September 25, 2015
News Industry News CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System September 21, 2015
News Industry News Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints September 16, 2015
News Daily News Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib August 04, 2015
News Industry News First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate) July 29, 2015
News Daily News Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene L.A. McKeown July 13, 2015
News Daily News After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist L.A. McKeown July 13, 2015
News Daily News Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding Yael L. Maxwell July 10, 2015
News Daily News La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias Yael L. Maxwell July 10, 2015
News Daily News Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib L.A. McKeown July 08, 2015
News Daily News RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis June 25, 2015
News Industry News Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C June 25, 2015
News Industry News Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study June 22, 2015